Kumuda — Actionable Insights For Drug Discovery

Platform that identifies and accelerates development of multiple novel drugs addressing high value clinical needs

The problem

Drug discovery is highly inefficient and current drugs only address roughly 1% to 2% of the human genome. In addition, finding new, successful drugs has become so much harder. The average cost of bringing one to market is $2.6B, a number that has nearly doubled between 2003 and 2013. There is an urgent need to rapidly discover and develop drugs for new disease targets, whether it’s to address the current COVID-19 pandemic, or for the large number of diseases that still lack effective treatments today.

What The Company Does

Kumuda effectively leverages the wealth of large-scale orthogonal and multi-faceted data sets available to generate actionable insights for drug discovery, and comprehensively assess a target’s potential to be drugged. This includes analysis of over 4 million bio-activities, roughly 16,000 crystal structures, and over 12,500 protein interactions. Kumuda’s methodology has not only identified hundreds of first-in-class small molecule drug target families, but has repeatedly accelerated the time and cost to clinic across a range of diseases. For a…